Computed Tomography Findings as Determinants of Local and Systemic Inflammation Biomarkers in Interstitial Lung Diseases: A Retrospective Registry-Based Descriptive Study

Lang, David; Akbari, Kaveh; Hörner, Andreas; Hepp, Magdalena; Kaiser, Bernhard; Pieringer, Herwig; Lamprecht, Bernd

doi:10.1007/s00408-021-00434-w

Cited by 7 publications

(5 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cells showing a higher abundance in BAL were macrophages and lymphocytes. These findings correspond to the findings previously reported in ASSD ( Lang et al., 2021 ) and other interstitial diseases, such as rheumatoid arthritis associated with ILD ( Lee et al., 2005 ).…”

Section: Discussionsupporting

confidence: 92%

Lung microbiome alterations in patients with anti-Jo1 antisynthetase syndrome and interstitial lung disease

Quintero-Puerta,

Lira-Lucio,

Falfán-Valencia

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

AimTo characterize the lung microbiome in the bronchoalveolar lavage fluid (BALF) of patients with Antisynthetase Syndrome (ASSD) according to anti-Jo1 autoantibody positivity and evaluate the correlation with differential cell count and other bacterial genera in BALF.MethodsWe sequenced the 16S ribosomal RNA gene in the BALF of anti-Jo1-positive (JoP, n=6) and non-Jo1-positive (NJo, n=17) patients, and the differential cell count in BALF was evaluated. The Spearman’s correlation was calculated for the quantitative variables and abundance of bacterial species.ResultsThe Veillonella genus showed a significant decrease (p<0.01) in JoP (2.2%) in comparison to NJo (4.1%) patients. The correlation analysis showed several high (rho ≥ ± 0.7) and significant (p < 0.05) correlations. We analyzed the results obtained for the Veillonella genera and other study variables. The JoP group showed that the abundance of Veillonella had a high negative correlation with macrophages (rho = - 0.77) and a positive correlation with eosinophils (rho = 0.77), lymphocytes (rho = 0.77), and Prevotella (rho = 1).ConclusionsThe lung microbiome in ASSD patients differs and may affect cell composition, contributing to lung damage mechanisms. The presence of anti-Jo1 autoantibodies showed a low abundance of Veillonella. This genus had a strong and positive correlation with Prevotella abundance and levels of eosinophils and lymphocytes, and it showed a strong negative correlation with the percentage of macrophages.

show abstract

Section: Discussionsupporting

confidence: 92%

Lung microbiome alterations in patients with anti-Jo1 antisynthetase syndrome and interstitial lung disease

Quintero-Puerta,

Lira-Lucio,

Falfán-Valencia

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…According to the radiologic characteristics of HRCT, histologic patterns, such as usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP), and organizing pneumonia (OP), were recognized ( 31 ). Concurrently, lesions observed radiologically were classified into inflammatory and fibrotic patterns ( 33 ).…”

Section: Methodsmentioning

confidence: 99%

Prognostic significance of natural killer cell depletion in predicting progressive fibrosing interstitial lung disease in idiopathic inflammatory myopathies

Shao,

Xia,

Zhen

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

ObjectivesInterstitial lung disease (ILD) is one of the common extramuscular involvement in idiopathic inflammatory myopathies (IIMs) (1). Several patients develop a progressive fibrosing ILD (PF-ILD) despite conventional treatment, resulting in a progressive deterioration in their quality of life (2). Here, we investigated the clinical and immune characteristics of IIM-ILD and risk factors for PF-ILD in IIM, mainly in anti-melanoma differentiation-associated protein 5 (anti-MDA5+) dermatomyositis (DM) and anti-synthetase syndrome (ASS).MethodsHere, a prospective cohort of 156 patients with IIM-ILD were included in the longitudinal analysis and divided into the PF-ILD (n=65) and non-PF-ILD (n=91) groups, and their baseline clinical characteristics were compared. Univariate and multivariate Cox analyses were performed to identify the variables significantly associated with pulmonary fibrosis progression in the total cohort, then anti-MDA5+ DM and ASS groups separately.ResultsPeripheral blood lymphocyte counts, including T, B, and NK cell counts, were significantly lower in the PF-ILD group than in the non-PF-ILD group. This characteristic is also present in the comparison between patients with anti-MDA5+ DM and ASS. The multivariate Cox regression analysis revealed that age > 43.5 years [HR: 7.653 (95% CI: 2.005-29.204), p = 0.003], absolute NK cell count < 148 cells/μL [HR: 6.277 (95% CI: 1.572-25.067), p = 0.009] and absolute Th cell count < 533.2 cells/μL [HR: 4.703 (95% CI: 1.014-21.821), p = 0.048] were independent predictors of progressive fibrosing during 1-year follow-up for patients with anti-MDA5+ DM, while absolute count of NK cells < 303.3 cells/µL [HR: 19.962 (95% CI: 3.108-128.223), p = 0.002], absolute count of lymphocytes < 1.545×109/L [HR: 9.684 (95% CI: 1.063-88.186), p = 0.044], and ferritin > 259.45 ng/mL [HR: 6 (95% CI: 1.116-32.256), p = 0.037] were independent predictors of PF-ILD for patients with ASS.ConclusionsPatients with anti-MDA5+ DM and ASS have independent risk factors for PF-ILD. Lymphocyte depletion (particularly NK cells) was significantly associated with PF-ILD within 1-year of follow-up for IIM-ILD

show abstract

“…As described in previous publications ( 30 , 31 ), all patients discussed by the local ILD-board were included into a prospective registry between 2017 and 2021. Patients enregistered had undergone standardized baseline evaluation including high-resolution computed tomography (HRCT), blood analyses including autoimmune antibody screening, and pulmonary functions tests (PFT).…”

Section: Methodsmentioning

confidence: 99%

“…If clinically feasible, prone imaging was preferred to differ opacities in dependent lung areas from true interstitial lung abnormalities ( 33 ). During the respective ILD-board session, a specialist ILD-radiologist assessed the presence of parenchymal nodules, reticular abnormalities, honeycombing, consolidations, ground glass opacities, emphysema, mosaic attenuation, and traction bronchi(-ol)ectasis in an upper-, middle- and lower-lung area as defined by thirds of the largest cranio-caudal diameter in the sagittal reconstructions, leading to scores from zero to six, as described for our previously reported evaluations ( 30 , 31 ). Each finding was then scored as absent, limited or abundant using cut-off values based on statistical modeling of the leading variables as explicated below.…”

Section: Methodsmentioning

confidence: 99%

Clinical, imaging, and blood biomarkers to assess 1-year progression risk in fibrotic interstitial lung diseases—Development and validation of the honeycombing, traction bronchiectasis, and monocyte (HTM)-score

et al. 2022

Self Cite

View full text Add to dashboard Cite

IntroductionProgression of fibrotic interstitial lung disease (ILD) leads to irreversible loss of lung function and increased mortality. Based on an institutional ILD registry, we aimed to evaluate biomarkers derived from baseline patient characteristics, computed tomography (CT), and peripheral blood for prognosis of disease progression in fibrotic ILD patients.MethodsOf 209 subsequent ILD-board patients enregistered, 142 had complete follow-up information and were classified fibrotic ILD as defined by presence of reticulation or honeycombing using a standardized semi-quantitative CT evaluation, adding up typical ILD findings in 0–6 defined lung fields. Progression at 1 year was defined as relative loss of ≥10% in forced vital capacity, of ≥15% in diffusion capacity for carbon monoxide, death, or lung transplant. Two-thirds of the patients were randomly assigned to a derivation cohort evaluated for the impact of age, sex, baseline lung function, CT finding scores, and blood biomarkers on disease progression. Significant variables were included into a regression model, its results were used to derive a progression-risk score which was then applied to the validation cohort.ResultsIn the derivation cohort, age, monocyte count ≥0.65 G/L, honeycombing and traction bronchiectasis extent had significant impact. Multivariate analyses revealed the variables monocyte count ≥0.65 G/L (1 point) and combined honeycombing or traction bronchiectasis score [0 vs. 1–4 (1 point) vs. 5–6 lung fields (2 points)] as significant, so these were used for score development. In the derivation cohort, resulting scores of 0, 1, 2, and 3 accounted for 1-year progression rates of 20, 25, 46.9, and 88.9%, respectively. Similarly, in the validation cohort, progression at 1 year occurred in 0, 23.8, 53.9, and 62.5%, respectively. A score ≥2 showed 70.6% sensitivity and 67.9% specificity, receiver operating characteristic analysis for the scoring model had an area under the curve of 71.7%.ConclusionThe extent of honeycombing and traction bronchiectasis, as well as elevated blood monocyte count predicted progression within 1 year in fibrotic ILD patients.

show abstract

Computed Tomography Findings as Determinants of Local and Systemic Inflammation Biomarkers in Interstitial Lung Diseases: A Retrospective Registry-Based Descriptive Study

Cited by 7 publications

References 45 publications

Lung microbiome alterations in patients with anti-Jo1 antisynthetase syndrome and interstitial lung disease

Lung microbiome alterations in patients with anti-Jo1 antisynthetase syndrome and interstitial lung disease

Prognostic significance of natural killer cell depletion in predicting progressive fibrosing interstitial lung disease in idiopathic inflammatory myopathies

Clinical, imaging, and blood biomarkers to assess 1-year progression risk in fibrotic interstitial lung diseases—Development and validation of the honeycombing, traction bronchiectasis, and monocyte (HTM)-score

Contact Info

Product

Resources

About